Speaker Lecture Titles

For the full program, click here

For plenary speakers, click here

For additional speakers, click here​


SurnameFirst nameCountryAbstract Title
A. PascoalTharickCanadaTHE SYNERGY BETWEEN AMYLOID-Β AND A HYPOMETABOLIC DEFAULT MODE NETWORK DETERMINES COGNITIVE DECLINE IN HUMANS AND TRANSGENIC RATS
AbisambraJoseUSAPERK INHIBITION DEMONSTRATES A NOVEL PATHOLOGICAL MECHANISM IN TAUOPATHIES
AbnerErinUSACLINICAL AND NEUROPATHOLOGICAL OUTCOMES AFTER DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT
AbrahamCarmelaUSAMODULATING KLOTHO EXPRESSION TOWARDS A NEW TREATMENT FOR ALZHEIMER’S DISEASE
AbudEdselUSAHUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS TO STUDY ALZHEIMER’S DISEASE
AbushakraSusanUSAPERSISTENT EFFICACY OF TRAMIPROSATE IN APOE4 HOMOZYGOUS AD SUBJECTS TREATED OVER 130 WEEKS: RESULTS OF NORTH AMERICAN EXTENSION STUDY
AdaikkanChinnakkaruppanUSALIGHT FLICKER MEDIATED GAMMA FREQUENCY ENTRAINMENT: A NON-INVASIVE APPROACH THAT ENHANCES COGNITIVE ABILITIES AND OFFERS NEUROPROTECTION IN MICE
AignerLudwigAustriaTHE ANTI-ASTHMATIC DRUG MONTELUKAST ALTERS MICROGLIA PHENOTYPE AND SYNUCLEOPATHY, AND RESTORES LEARNING AND MEMORY IN AN ANIMAL MODEL OF LEWY BODY DEMENTIA.
AndoKunieBelgiumALZHEIMER RISK FACTOR PICALM LOCALIZATION AND PROTEIN SOLUBILITIES ARE ALTERED IN TAUOPATHIES AND ARE CORRELATED WITH AUTOPHAGY MARKERS
AndreassonKatrinUSATHE KYNURENINE PATHWAY IN AD: CONTRIBUTION TO PATHOGENESIS THROUGH MODULATION OF IMMUNE CELL RESPONSES AND BIOENERGETICS
AnichtchikOlegUnited KingdomBETA-SYNUCLEIN CHANGES IN POST-MORTEM CORTEX OF DEMENTIA WITH LEWY BODIES PATIENTS
AnkarcronaMariaSwedenAMYLOID BETA-PEPTIDE AFFECTS THE STRUCTURE AND DYNAMICS OF ER-MITOCHONDRIA CONTACT SITES IN ALZHEIMER’S DISEASE RELATED MODELS
ApostolovaLianaUSAPATIENT AND CAREGIVER VIEWS ON AMYLOID PET IMAGING
Arango-LievanoMargaritaFranceDELETION OF NEUROTROPHIN SIGNALING THROUGH THE GLUCOCORTICOID RECEPTOR PATHWAY CAUSES TAU NEUROPATHOLOGY
Arbel-OrnathMichalUSASTRUCTURAL AND FUNCTIONAL ALTERATIONS OF BRAIN VASCULATURE IN CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER’S DISEASE
AsheKarenUSACASPASE-2 CLEAVING TAU REVERSIBLY IMPAIRS MEMORY
AsheryUriIsraelMULTIFACETED MITIGATING EFFECTS OF HYPERBARIC OXYGEN THERAPY IN ALZHEIMER’S DISEASE MOUSE MODELS
AsnaghiVeronicaSwitzerlandLONG-TERM SAFETY AND TOLERABILITY OF ESCALATING DOSES OF CRENEZUMAB IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE
AvaleMaria-ElenaArgentinaMODULATION OF 3R:4R TAU ISOFORMS BY RNA REPROGRAMMING: FUNCTIONAL CONSEQUENCES AND THERAPEUTIC PERSPECTIVES
AvantsBrianUSAAMYLOID POSITIVE SUBJECTS EXHIBIT LONGITUDINAL REDUCTIONS IN DEFAULT MODE NETWORK SPONTANEOUS BRAIN ACTIVITY OVER A TWO YEAR PERIOD
AyalonGaiUSAPRECLINICAL CHARACTERIZATION, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS AND SAFETY OF RO7105705 – AN ANTI-TAU ANTIBODY CURRENTLY IN CLINICAL DEVELOPMENT FOR ALZHEIMER’S DISEASE
AytonScottAustraliaIN VIVO MAPPING OF BRAIN IRON AND ITS RELATIONSHIP WITH AMYLOID BURDEN AND COGNITIVE DECLINE
Baglietto-VargasDavidUSAAPPKI-HAΒWT: A NEW ANIMAL MODEL FOR SPORADIC ALZHEIMER’S DISEASE
BarangerKevinFranceMT5-MMP PROMOTES ALZHEIMER’S PATHOGENESIS IN THE FRONTAL CORTEX OF 5XFAD MICE AND APP TRAFFICKING IN VITRO
BartelsTimUSAA UNIVERSAL AGGREGATION MECHANISM FOR FAMILIAL ALPHA-SYNUCLEIN MUTATIONS IN PRION-LIKE SPREAD
BatemanRandallUSAFROM TRANSLATIONAL RESEARCH TO PREVENTION TRIALS: TARGETING THE PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE
BeherDirkSwitzerlandNEXT GENERATION OF HIGHLY BRAIN PENETRANT O-GLCNACASE INHIBITORS AS ORALLY BIOAVAILABLE MODIFIERS OF NEUROFIBRILLARY TANGLE FORMATION FOR THE TREATMENT OF TAUOPATHIES
BennettSteffanyCanadaTRANSLATIONAL LIPIDOMICS: CAN PATIENTS WITH DLB, ALZHEIMER’S OR MCI BE STRATIFIED BY INTERROGATING THEIR PLASMA LIPIDOMES?
BezprozvannyIlyaUSASYNAPTIC STORE-OPERATED CALCIUM ENTRY PATHWAY AS NOVEL TARGET FOR AD THERAPEUTICS
BingolBarisUSAMITOPHAGY PATHWAYS IN PARKINSON'S DISEASE
BlancFredericFranceLONG TERM COGNITIVE OUTCOME OF DEMENTIA WITH LEWY BODIES AND ALZHEIMER’S DISEASE: DUAL PATHOLOGY IS WORSE
BlauwendraatCornelisUSASCREENING OF PATHOGENIC AND RISK VARIANTS IN NEURODEGENERATIVE DISEASES USING THE NEW NEUROCHIP ARRAY
BlennowKajSwedenFLUID BIOMARKERS IN ALZHEIMER’S DISEASE TRIALS: TOOLS FOR DIAGNOSTIC ENRICHMENT AND TO IDENTIFY DRUG EFFECTS ON PATHOPHYSIOLOGY
Blesa GonzalezRafaelSpainTHE IMPACT OF OBESITY AND WEIGHT LOSS ON BRAIN STRUCTURE: A 2-YEARS PROSPECTIVE STUDY
BolotinaVictoriaUSAIMPAIRMENT OF PARK14-DEPENDENT CA2+ SIGNALING AS A NOVEL DETERMINANT OF HUMAN PARKINSON'S DISEASE
BonventoGillesFranceMETABOLIC DEPLETION OF L-SERINE IN ASTROCYTES IMPAIRS SYNAPTIC PLASTICITY IN A MOUSE MODEL OF ALZHEIMER'S DISEASE
BouvierDavidLuxembourgIMPACT OF MICROGLIA ON THE HIPPOCAMPUS DETERIORATION IN ALZHEIMER’S DISEASE
BradshawElizabethUSASHARED POLYGENIC CONTRIBUTIONS TO NEURODEGENERATIVE AND IMMUNE-RELATED TRAITS REVEALS EFFECTS OF SUSCEPTIBILITY LOCI ON MICROGLIAL ACTIVATION
BrionJean-PierreBelgiumPHF FROM ALZHEIMER BRAIN INDUCE SEEDING OF AN ARGYROPHILIC 4R TAU PATHOLOGY IN WILD-TYPE MICE
BrudekTomaszDenmarkSHIFT IN ANTI-ALPHA-SYNUCLEIN AUTOANTIBODY PATTERNS IN PARKINSON’S DISEASE AND MULTIPLE SYSTEM ATROPHY
BrysMiroslawUSARANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY OF ANTI-ALPHA-SYNUCLEIN ANTIBODY BIIB054 IN HEALTHY VOLUNTEERS
BuBuojunUSACENTRAL AND PERIPHERAL APOE IN COGNITION AND AD
BuéeLucFranceTAU STRAINS AND MECHANISMS OF PRION-LIKE PROPAGATION
BurnhamSamanthaAustraliaESTIMATING THE AGE OF ONSET FOR BIO-MARKERS OF AD
ButovskyOlegUSATHE TREM2-APOE PATHWAY INDUCES DYSFUNCTIONAL MICROGLIA IN NEURODEGENERATION
ButtiniManuelLuxembourgAGGREGATION-INDEPENDENT NEURODEGENERATION AND MICROGLIOSIS IN A MOUSE MODEL OF PRION-LIKE ALPHA-SYNUCLEIN SPREADING.
CacaceRitaBelgiumIDENTIFICATION OF DIPEPTIDYL PEPTIDASE 6 AS A NOVEL CANDIDATE IN NEURODEGENERATIVE BRAIN DISEASES
Calatayud AristoyCarlesSpainDISSECTING PARKINSON’S DISEASE GENETIC COMPLEXITY BY COMBINING GENE EDITING AND PATIENT’S CELLS
CapotostiFrancescaSwitzerlandNOVEL PET TRACERS OF ALPHA-SYNUCLEIN FOR THE DIAGNOSIS OF PARKINSON'S DISEASE
CapotostiFrancescaSwitzerlandSMALL MOLECULES TARGETING TAU PROPAGATION DEMONSTRATE EFFICACY IN AN AGGRESSIVE TAUOPATHY MOUSE MODEL
CasadeiNicolasGermanyMODULATION OF THE GASTROINTESTINAL MICROBIOME INDUCED BY ALPHA-SYNUCLEIN OVEREXPRESSION IN PARKINSON´S DISEASE RODENT TRANSGENIC MODELS
CavalliniAnnalisaUnited KingdomCHARACTERISATION OF EXTRACELLULAR TAU IN CONDITIONED MEDIA FROM CELL MODELS OF TAU AGGREGATION
CeccaldiMathieuFranceIMPACT OF FLORBETABEN PET IMAGING ON DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH SUSPECTED AD ELIGIBLE FOR CSF ANALYSIS IN FRANCE
CheclerFrédéricFranceAUTOPHAGY IN ALZHEIMER: WHAT BESIDES ABETA?
ChenYun-Ru (Ruby)Taiwan R.O.C.UNDERSTANDING TDP-43 OLIGOMERS AND DIPEPTIDE REPEATS IN FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS
ChenLiamUSAIMPAIRED TDP-43 REPRESSION OF NONCONSERVED CRYPTIC EXONS IN ALZHEIMER’S DISEASE
ChéraudChrystelFranceAMYLOID PET IN DEMENTIA WITH LEWY BODIES IN THE EARLY STAGE
Chiba-FalekOrnitUSAREGULATION OF GENE EXPRESSION:  THE GENETIC MECHANISMS UNDERLYING NEURODEGENERATIVE DISEASES
CioffiFedericaThe NetherlandsTHE EFFECT OF SIMULTANEOUS ADMINISTRATION OF TWO PROTEOLYTIC ENZYMES ON THE CLEARANCE OF AMYLOID-BETA PEPTIDE
ClaeysenSylvieFranceIMPACT OF GUT MICROBIOTA IN A MOUSE MODEL OF ALZHEIMER'S DISEASE
ClevelandDonUSAGENE SILENCING THERAPY FOR HUMAN NEURODEGENERATIVE DISEASE
Colom-CadenaMartíSpainIMAGING SYNAPTIC PATHOLOGY IN DEMENTIA WITH LEWY BODIES
ConnollyNiamhIrelandTHE CELLULAR BIOENERGETICS IN NEURODEGENERATIVE DISEASES CONSORTIUM COMBINES SYSTEMS MODELLING WITH IN VITRO ANALYSIS TO INVESTIGATE NEURODEGENERATIVE MITOCHONDRIAL RESPIRATORY DYSFUNCTION IN AD, PD AND HD
CorriveauRoderickUSAVASCULAR CONTRIBUTIONS TO COGNITIVE IMPAIRMENT AND DEMENTIA (VCID) BIOMARKERS CONSORTIUM
CrestoNoemieFranceTHE LRRK2 G2019S MUTATION BUT NOT ITS DEAD KINASE FORM INCREASES THE NEUROTOXICITY OF MUTANT A53T A-SYNUCLEIN
CroftCaraUSABRAIN SLICE CULTURE MODELS OF TAUOPATHIES AND OTHER CNS PROTEINOPATHIES
CuelloClaudio A.CanadaAN EVOLVING METABOLIC NGF DEREGULATION IN THE ALZHEIMER’S AND DOWN SYNDROME PATHOLOGIES
Dalrymple-AlfordJohnNew ZealandPARKINSON’S DISEASE: OPTIMISING NEUROPSYCHOLOGICAL TESTING TO IDENTIFY RISK OF PROGRESSION TO DEMENTIA.
DawsonTedUSALYMPHOCYTE ACTIVATION GENE 3 IS THE NEURON TRANSMISSION RECEPTOR FOR PRIONIC SPREAD OF PATHOLOGIC ALPHA-SYNUCLEIN
De JagerPhilipUSATAU BUT NOT AMYLOID PATHOLOGY IS ASSOCIATED WITH LARGE-SCALE EPIGENOMIC CHANGES IN THE HUMAN BRAIN
De RoeckArneBelgiumDELETERIOUS ABCA7 MUTATIONS AND TRANSCRIPT RESCUE MECHANISMS IN EARLY-ONSET ALZHEIMER’S DISEASE
De StrooperBartBelgiumTHE CELLULAR PHASE OF ALZHEIMER DISEASE
De VosAnnBelgiumPROTEIN TAU PREDICTS STROKE SEVERITY AND OUTCOME IN ACUTE ISCHEMIC STROKE
DekensDoortjeThe NetherlandsESSENTIAL PROTECTIVE FUNCTION OF TUMOR NECROSIS FACTOR RECEPTOR 2 SIGNALLING IN ACUTE MODELS OF ALZHEIMER’S DISEASE
Del Campo MilanMartaThe NetherlandsBRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY
DeVosSarahUSAIN VIVO MONITORING AND ANALYSIS OF TAU AGGREGATION AND SPREADING
DewachterIlseBelgiumTAU-INTERACTOME MAPPING BASED IDENTIFICATION OF TAU MODIFIERS AND THEIR IN VITRO AND IN VIVO VALIDATION IN TAU TRANSGENIC MICE.
DhenainMarcFranceREORGANIZATION OF AMYLOID DISTRIBUTION PATTERNS FOLLOWING ALZHEIMER BRAIN HOMOGENATE INOCULATION IN TRANSGENIC MICE
DiamondMarcUSATAU PRION STRAINS AS THE BUILDING BLOCKS OF SYNDROMIC DIVERSITY IN TAUOPATHIES
DicksteinDaraUSA[18F]T807/AV-1451 (FLORTAUCIPIR) IMAGING IN ATHLETES WITH POSTCONCUSSIVE SYNDROMES INCLUDING CLINICALLY PROBABLE CTE: PROMINENCE OF PSYCHIATRIC CLINICAL SYMPTOMS AND IMPLICATIONS FOR EXPERIMENTAL THERAPY
Do CarmoSoniaCanadaDNA DEMETHYLATION AS A THERAPEUTIC TARGET IN ALZHEIMER’S DISEASE
DorostkarMarioGermanyQUANTIFICATION OF INHIBITORY AND EXCITATORY SYNAPSE LOSS IN ALZHEIMER'S DISEASE
DuffKarenUSAPROPAGATION OF TAU AS A THERAPEUTIC TARGET
DunahAnthoneUSAPICK1 IS A NOVEL SYNAPTO-PROTECTIVE TARGET FOR ALZHEIMER’S DISEASE
DuplanEricFranceP53 UPREGULATES Α-SYNUCLEIN: A MECHANISM THAT COULD CONTRIBUTE TO ACCUMULATION OF TOXIC AGGREGATED SYNUCLEIN IN PARKINSON’S DISEASE (PD)
DuttaAlokeUSAA NOVEL IRON (II) PREFERRING DOPAMINE AGONIST CHELATOR D-607 SIGNIFICANTLY SUPPRESSES Α-SYN- AND MPTP-INDUCED TOXICITIES IN VIVO
Dutta PasseckerPriyankaUnited KingdomFRONTOTEMPORAL DEMENTIA AND PARKINSON’S DISEASE CELLULAR MODELS: IN-VITRO CHARACTERIZATION OF PATHOLOGICAL PHENOTPYES IN GENE-EDITED IPSC-DERIVED NEURONS WITH MAPT AND LRRK2 MUTATIONS
EimerWilliamUSAALZHEIMER’S DISEASE ASSOCIATED PATHOLOGIES INDUCED BY PATHOGEN-MEDIATE BETA-AMYLOID DEPOSITION
EiseleYvonneUSAIDENTIFICATION AND CHARACTERIZATION OF NOVEL, HIGHLY STABLE, CYTOTOXIC TRANSTHYRETIN (TTR) OLIGOMERS IN TTR-RELATED AMYLOID DISORDERS
El-AgnafOmarQatarEXPLORING THE POTENTIAL ROLE OF ALPHA-SYNUCLEIN SPECIES AS PARKINSON’S DISEASE BIOMARKERS IN LRRK2 MUTATION CARRIERS COHORT.
Eldar-FinkelmanHagitIsraelNEW MODALITY OF GSK-3 INHIBITION HOLDS PROMISE IN TREATING NEURODEGENERATIVE DISORDERS
ElmsaouriSaraUSAIDENTIFYING MODULATORS OF GENOMIC STABILITY IN ALZHEIMER’S DISEASE
EndresKristinaGermanyALTERED GUT MICROBIOME COMPOSITION AND DIGESTIVE ENZYME ACTIVITY OF THE 5XFAD ALZHEIMER MOUSE MODEL
ErskineDanielUnited KingdomSUBCORTICAL VISUAL SYSTEM PATHOLOGY AND HALLUCINATIONS IN DEMENTIA WITH LEWY BODIES
EskildsenSimonDenmarkCORTICAL CAPILLARY DYSFUNCTION IS ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE
EspositoGiuseppeItalyAUTOLOGOUS TRANSPLANTATION OF ENTERIC GLIA IMPROVES NEUROPATHOLOGY AND RESTORES COGNITIVE DEFICITS IN Β AMYLOID-INDUCED NEURODEGENERATION.
FahnestockMargaretCanadaTAU MODULATES BDNF EXPRESSION AND MEDIATES AΒ-INDUCED BDNF DOWN-REGULATION IN ANIMAL AND CELLULAR MODELS OF ALZHEIMER’S DISEASE
FalahatiFarshadSwedenASSOCIATIONS OF LONGITUDINAL BRAIN STRUCTURAL CHANGES WITH COGNITION, APOE GENOTYPE AND AMYLOID BURDEN IN MILD COGNITIVE IMPAIRMENT
FarrerLindsayUSANOVEL GENETIC VARIANTS AND LOCI INFLUENCING RISK OF ALZHEIMER’S DISEASE IDENTIFIED BY WHOLE EXOME SEQUENCING USING AN ENRICHED CASE-CONTROL DESIGN
FerreiraDanielSwedenSUBJECTIVE MEMORY DECLINE: ATROPHY PATTERNS, COGNITION, AMYLOID BURDEN AND CLINICAL PROGRESSION OVER 7.5 YEARS
FerrettiMaria TeresaSwitzerlandALZHEIMER PATHOLOGY, T CELL EXTRAVASATION AND CHOROID PLEXUS ACTIVATION - A PILOT STUDY IN HUMAN POST-MORTEM SAMPLES
FfytcheDominicUnited KingdomBIOMARKERS OF EARLY-ONSET PSYCHOSIS IN PARKINSON’S DISEASE
ForteaJuanSpainMICROSTRUCTURAL CORTICAL CHANGES ALONG THE ALZHEIMER'S DISEASE CONTINUUM
FrenkelDanIsraelTHE LINK BETWEEN PRESENILIN TO MICROGLIA ACTIVITY IN ALZHEIMER'S DISEASE
FriedlandRobertUSATHE INFLUENCE OF BACTERIAL AMYLOID ON ALPHA SYNUCLEIN (AS) AGGREGATION AND NEUROINFLAMMATION IN THE RAT AND CAENORHABDITIS ELEGANS
FrisoniGiovani BItalyBIOMARKER MATRIX SENSITIVE TO THE PROGRESSION OF ALZHEIMER’S DISEASE
FunamotoSatoruJapanPOTENTIAL DETERMINATION MECHANISM OF EPSILON-CLEAVAGE SITES: IMPLICATION FOR DETERMINANTS OF ABETA40 AND ABETA42 PRODUCTION LINES
FutermanTonyIsraelUNRAVELING THE MECHANISTIC CONNECTION BETWEEN GBA1 MUTATIONS AND PARKINSON’S DISEASE
GanzAndreaThe NetherlandsNEUROPATHOLOGICAL ASSESSMENT OF COGNITIVELY HEALTHY CENTENARIANS – THE 100-PLUS STUDY
Garcia ReitboeckPabloUnited KingdomINDUCED PLURIPOTENT STEM CELL-­DERIVED MACROPHAGES AS A MODEL TO STUDY THE ROLE OF TREM2 IN ALZHEIMER’S DISEASE
GarnHeinrichAustriaAPPLICATION OF THE QUANTITATIVE ELECTROENCEPHALOGRAM IN DEMENTIA DIAGNOSIS
GeulaChangizUSAAGE-RELATED INTRANEURONAL CALCIUM DYSREGULATION AND NEURONAL VULNERABILITY IN ALZHEIMER’S DISEASE
GhisoJorgeUSAAMYLOID BETA CATABOLISM: A BALANCING ACT BETWEEN EFFECTIVE BRAIN CLEARANCE  AND THE PROCESS OF AMYLOIDOGENESIS
GiladiNirIsraelPERSONALIZED APPROACH TO PD TREATMENT, THE ROLE OF MUTATIONS IN THE GBA AND LRRK2 GENES
GoldGabrielSwitzerlandSORTING OUT THE COGNITIVE IMPACT OF CEREBRAL MICROINFARCTS AND MICROBLEEDS
GoldeToddUSATARGETING IMMUNOPROTEOSTASIS IN AD AND PD
GoldhardtOliverGermanyKALLIKREIN-RELATED PEPTIDASES IN ALZHEIMER’S DISEASE – SUITABLE BIOMARKERS FOR AMYLOID PATHOLOGY?
GompertsStephenUSAPET IMAGING OF TAU AGGREGATES IN THE LEWY BODY DISEASES
GrahamLeahUSADIET-INDUCED NEUROINFLAMMATION AND VASCULAR DYSFUNCTION CAUSE WHITE MATTER DAMAGE IN THE AGING BRAIN
GrassetLeslieFranceTIME TRENDS IN LEVEL AND DECLINE OF COGNITION AND FUNCTION OF ELDERLY PEOPLE  10 YEARS APART:  THE PAQUID STUDY
GrimmerTimoGermanyALTERED NEURO-VASCULAR COUPLING IN ALZHEIMER DISEASE AS MEASURED BY OPTICAL IMAGING: A PROMISING BIOMARKER
GrowdonJohn H.USANEUROIMAGING BIOMARKERS IN LEWY BODY DISEASES:  NEUROPATHOLOGIC CONFIRMATION
GuptaVeer BalaAustraliaESTABLISHING A LINK BETWEEN PROTEIN METABOLISM AND ALZHEIMER’S DISEASE: BASED ON THE LONGITUDINAL PROTEOMICS DATA FROM AN AGING COHORT
HaassChristianGermanyTREM2 - FROM CELLULAR MECHANISMS TO HUMAN PATIENTS
HainesJonathanUSAIN SILICO FUNCTIONAL ANNOTATION OF GENOMIC VARIANTS AND MULTI-GENE ANALYSES IN LATE ONSET ALZHEIMER’S DISEASE
Hajos-KorcsokEvaUSAPRECLINICAL PHARMACOLOGY AND TOXICOLOGY OF PF-06648671, A NOVEL GAMMA SECRETASE MODULATOR: COMPARISON TO GAMMA SECRETASE INHIBITORS
HallHeleneCanadaTARGETING M1 MUSCARINIC AND SIGMA-1 RECEPTORS IN ALZHEIMER'S DISEASE: REVERSAL OF PATHOLOGICAL HALLMARKS AND ASSOCIATED COGNITIVE DYSFUNCTION IN MCGILL-R-THY1-APP RATS
HallSaraSwedenBLOOD-BASED NFL: A BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS
HammMatthewUSAPHOSPHORYLATION AT A LRRK2-TARGETED TAU EPITOPE REVEALS NOVEL PATHOLOGICAL STAINING IN TAUOPATHIES
HangerDianeUnited KingdomA HUMAN TAUOPATHY-ASSOCIATED TAU FRAGMENT INDUCES MOTOR AND COGNITIVE DEFICITS AND TAU AGGREGATION IN MICE
HanssonOskarSwedenCONCORDANCE BETWEEN NEW ELECSYS(R) CSF ASSAYS (ABETA(1-42), TOTAL TAU AND PHOSPHORYLATED TAU) AND AMYLOID PET IMAGING IN BIOFINDER AND ADNI
HardyJohnUnited KingdomGENETICS OF THE LYSOSOME AND PARKINSON’S DISEASE
HarrisonIanUnited KingdomGLYMPHATIC CLEARANCE IMPAIRED IN A MOUSE MODEL OF TAUOPATHY: CAPTURED USING CONTRAST-ENHANCED MRI
HartmannTobiasGermanyBIOMARKER RESULTS OF THE LIPIDIDIET TRIAL ON FORTASYN CONNECT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE
HarveyKirstenUnited KingdomWNT AND CA2+ SIGNALLING CHANGES IN LRRK2 PARKINSON’S DISEASE MODELS
HecimovicSilvaCroatiaBACE1-CLEAVAGE OF SEZ6 AND SEZ6L PROTEINS IS ENHANCED IN NIEMANN-PICK TYPE C DISEASE MODELS
HelwigMichaelGermanyWHOLE BRAIN IMAGING AND 3D-MODELING OF ALPHA-SYNUCLEIN TRANSMISSION IN OPTICALLY CLEARED MOUSE TISSUE
HenjumKristiNorwayCEREBROSPINAL FLUID SOLUBLE TREM2 IN AGING AND ALZHEIMER’S DISEASE
HermsJochenGermanyBACE1 INHIBITION IN AD THERAPY AND ITS POTENTIAL SYNAPTIC SIDE EFFECTS - A WALK ON A TIGHTROPE?
HockChristophSwitzerlandANTIBODY THERAPY FOR ALZHEIMER’S DISEASE - KEY CHALLENGES
HolstegeHenneThe NetherlandsPROTEIN TRUNCATING AND RARE DAMAGING VARIANTS IN THE SORL1 GENE CAUSE ALZHEIMER’S DISEASE
HoltzmanDavidUSAEFFECTS OF APOE ON TAU AND NEURODEGENERATION
HondiusDavidThe NetherlandsPROTEOMICS ANALYSIS OF CAPILLARY CEREBRAL AMYLOID ANGIOPATHY
HoozemansJeroenThe NetherlandsUNFOLDED PROTEIN RESPONSE ACTIVATION IN C9ORF72 FRONTOTEMPORAL DEMENTIA CASES
HortJakubCzech RepublicCLINICAL AND RESEARCH UTILITY OF SPATIAL NAVIGATION ASSESSMENT IN ALZHEIMER´S DISEASE
HorvathIstvanSwedenCROSS-TALK BETWEEN AMYLOIDOGENIC PROTEINS IN TYPE-2 DIABETES AND PARKINSON’S DISEASE
HoubenSarahBelgiumEXPRESSION OF FTDP-17 MUTANT TAU IN TRANSGENIC MICE DECREASES ADULT NEUROGENESIS IN THE DENTATE GYRUS
HudryEloiseUSAAPOLIPOPROTEIN E: A COMPLEX MODULATOR OF NEURONAL NETWORK INTEGRITY IN PHYSIOLOGICAL AND PATHOLOGICAL CONTEXTS
HugonJacquesFranceTHERAPEUTIC STRATEGIES WITH PKR AND JNK INHIBITIONS: PRECLINICAL AND CLINICAL FINDINGS
HultqvistGretaSwedenBIVALENT BRAIN SHUTTLE INCREASES ANTIBODY UPTAKE BY MONOVALENT BINDING TO THE TRANSFERRIN RECEPTOR
HymanBradleyUSAMOLECULAR UNDERPINNINGS OF PROGRESSION IN ALZHEIMER’S DISEASE
InestrosaNibaldo C.ChileNEUROPROTECTION OF AD IN OCTODON DEGUS: ROLE OF WNT PATHWAY
IqbalKhalidUSAPASSIVE IMMUNIZATION TARGETING AMINO-TERMINAL OF TAU INHIBITS NOT ONLY TAU BUT ALSO ABETA PATHOLOGY
IsacsonOleUSATHE CONVERGENCE OF LYSOSOMES AND LIPIDS IN NEURODEGENERATION
IshiiMakotoUSABODY WEIGHT DEFICITS AND ALTERATIONS IN PLASMA ADIPOKINE LEVELS IN THE PRECLINICAL STAGE OF ALZHEIMER’S DISEASE
IttnerLarsAustraliaON THE MOLECULAR ROLE OF TAU IN REGULATING POST-SYNAPTIC TOXICITY
IwatsuboTakeshiJapanJAPANESE ADNI: OVERVIEW OF THE CLINICAL AND IMAGING DATA
JacksonJohannaUnited KingdomIN VIVO TWO-PHOTON IMAGING OF THE EFFECTS OF TAUOPATHY AND AMYLOIDOPATHY ON SYNAPSES
JäkelLiekeThe NetherlandsPATHOBIOLOGICAL CHARACTERISTICS OF AMYLOID-BETA43 AND AMYLOID-BETA(PE3)42: MISSING PEPTIDES IN CAA
JangMing-KueiTaiwan R.O.C.NOVEL IMAGING TRACERS, 18F-PM-PBB3 AND 18F-AM-PBB3, FOR VISUALIZATION AND QUANTIFICATION OF FIBRILLARY TAU PATHOLOGIES WITH POSITRON EMISSIONN TOMOGRAPHY
JankovicJosephUSARESULTS FROM A PHASE 1B MULTIPLE ASCENDING-DOSE STUDY OF PRX002, AN ANTI-ALPHA-SYNUCLEIN MONOCLONAL ANTIBODY, IN PATIENTS WITH PARKINSON’S DISEASE
JankowskyJoannaUSAA NEW CHEMOGENETIC SYSTEM FOR MODELING CIRCUIT DYSFUNCTION IN NEURODEGENERATIVE DISEASE
JensenPoul HenningDenmarkREDUCED CYTOSOLIC CALCIUM CAUSED BY SERCA ACTIVATION IS AN EARLY AND PATHOGENIC EVENT IN THE NEURODEGENERATION CAUSED BY ALPHA-SYNUCLEIN OLIGOMERS
JeonBeomseokKoreaRBD [REM SLEEP BEHAVIOR DISORDER] AND PARKINSON'S DISEASE PROGNOSIS
JohnsonKeithUSASTAGING AD PATHOLOGY WITH PET
JørgensenArne LundDenmarkDEVELOPMENT OF A LARGE ANIMAL MODEL OF ALZHEIMER’S DISEASE IN GOTTINGEN MINIPIGS
KarampetsouMantiaGreecePHOSPHORYLATED ALPHA-SYNUCLEIN FIBRILS PROMOTE PATHOLOGY AND NEURODEGENERATION IN VIVO
KeatorDavidUSABASELINE [18F]AV-45 PET PREDICTORS OF DEMENTIA TRANSITION IN DOWN SYNDROME
KielyAoifeUnited KingdomALPHA-SYNUCLEIN DEGRADATION IN MULTIPLE SYSTEM ATROPHY
KimJungsuUSAMICRORNA-874 DOWNREGULATES BACE1 EXPRESSION AND DRAMATICALLY INHIBITS AMYLOID ACCUMULATION IN THE BRAIN
KinsStefanGermanyAPLP1 IS A SYNAPTIC CELL ADHESION MOLECULE, SUPPORTING MAINTENANCE OF DENDRITIC SPINES AND BASAL SYNAPTIC TRANSMISSION
KitazumeShinobuJapanENDOTHELIAL O-GALNAC GLYCOSYLATION PATHWAY DETERMINES APP PROCESSING FOR VASCULAR AΒ DEPOSITION
KlenermanDavidUnited KingdomDETECTING AND CHARACTERISING INDIVIDUAL OLIGOMERS PRESENT IN HUMAN CSF
KoflerJuliaUSATHE PSYCHOSIS PHENOTYPE OF ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED TAU BURDEN AND SHIFT IN MICROGLIAL ACTIVATION
KooEdwardUSASYNAPTIC INJURY IN ALZHEIMER DISEASE: INSIGHTS FROM TARGETED EXPRESSION OF APP AND TAU IN MICE
KoprichJamesCanadaREPRODUCIBILITY OF A MACAQUE MODEL OF PARKINSON'S DISEASE ALPHA-SYNUCLEINOPATHY
KorczynAmosIsraelIS PARKINSON REALLY A PRION DISEASE?
KorhonenVilleFinlandC9ORF72 EXPANSION ASSOCIATED IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS: A POTENTIAL COMORBIDITY WITH BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA
KouroupiGeorgiaGreeceDEFECTIVE SYNAPTIC CONNECTIVITY AND AXONAL NEUROPATHOLOGY IN A HUMAN IPSC-BASED MODEL OF FAMILIAL PARKINSON'S DISEASE
KovacsGabor G.AustriaEVALUATING THE PATTERNS OF AGING-RELATED TAU ASTROGLIOPATHY (ARTAG) UNRAVELS NOVEL INSIGHTS INTO BRAIN-AGEING AND NEURODEGENERATIVE DISEASES
KovalEricaUSATREM2 GENETIC DELETION EXACERBATES THE DISEASE COURSE IN THE SOD1G93A MOUSE MODEL OF ALS
KratzerIngridAustriaNSC-COMPOUNDS, A NOVEL THIOPHENE SCAFFOLD, REDUCE AMYLOID AND P-TAU, AND IMPROVE SPATIAL MEMORY IN A MOUSE MODEL OF ALZHEIMER’S DISEASE
KrumpolecPatrikSlovak RepublicBENEFITS OF ENDURANCE-STRENGTH TRAINING IN PATIENTS WITH PARKINSON'S DISEASE
KulisevskyJaimeSpainHALLUCINATIONS IN PARKINSONS DISEASE
LammichSvenGermanyBACE1 TRANSLATION IS FACILITATED BY AN IRE1 MEDIATED ENDONUCLEOLYTIC CLEAVAGE OF ITS INHIBITORY 5'UTR
LanzillottaChiaraItalyTHE UNFOLDED PROTEIN RESPONSE IS A MAJOR PARTICIPANT IN THE DEVELOPMENT OF ALZHEIMER DISEASE SYMPTOMATOLOGY IN A MOUSE MODEL OF DOWN SYNDROME
LautenschlägerJaninUnited KingdomALPHA-SYNUCLEIN - SUPER-RESOLUTION MICROSCOPY REVEALS POTENTIAL NEW ROLE AT THE PRE-SYNAPSE
LaVoieMattUSACELL AUTONOMOUS AND NON-AUTONOMOUS G2019S LRRK2 DYSFUNCTION
LazarovOrlyUSAMECHANISMS OF COGNITIVE DEFICITS AND BLOOD BIOMARKERS IN ALZHEIMER’S DISEASE
LealNuno SantosSwedenMODULATION OF ER-MITOCHONDRIA CONTACTS SITES INFLUENCE AUTOPHAGOSOME PRODUCTION
LeBlancAndreaCanadaCASPASE-6, AS A NOVEL THERAPEUTIC TARGET OF AGE-DEPENDENT COGNITIVE IMPAIRMENT AND ALZHEIMER DISEASE.
LeeVirginia M.Y.USATRANSMISSION OF Α-SYNUCLEIN STRAINS IN SYNUCLEINOPATHIES
LeeDong YoungRepublic of KoreaKOREAN BRAIN AGING STUDY FOR EARLY DIAGNOSIS AND PREDICTION OF ALZHEIMER’S DISEASE (KBASE)
LeeSeung-JaeRepublic of KoreaROLE OF LYSOSOME IN PROTEIN AGGREGATE PROPAGATION
LeeEdwardUSALOSS OF TDP-43 CONTRIBUTES TO NON-CODING RNA MEDIATED TOXICITY
LehtonenSarkaFinlandINVESTIGATING PARKINSONʼS DISEASE USING HUMAN STEM CELL-DERIVED ASTROCYTES
LemereCynthiaUSAMURINE ANTI-PYROGLUTAMATE-3 ABETA MAB, 07/2A, SPARES COGNITION, REDUCES PLAQUES AND IN COMBINATION WITH GLUTAMINYL CYCLASE INHIBITOR PQ912 FURTHER IMPROVES EFFICACY
LeroyKarelleBelgiumDELETION OF AMYLOID PRECURSOR PROTEIN EXACERBATES THE PHOSPHORYLATION AND AGGREGATION OF TAU IN MICE EXPRESSING HUMAN MUTANT TAU
LevitesYonaUSACOMBINATION OF PRO-INFLAMMATORY INTERLEUKIN 6 AND ANTI-INFLAMMATORY INTERLEUKIN 10 WITH ANTI-AMILOID BETA IMMUNOTHERAPY AFFECTS AMYLOID DEPOSITION IN AD MOUSE MODEL
LevyEfratUSAA MECHANISM FOR ENHANCED EXOSOME SECRETION IN THE BRAIN OF DOWN SYNDROME PATIENTS THAT ALLEVIATES NEURONAL ENDOSOMAL ABNORMALITIES
LichtenthalerStefanGermanyTHE BETA-SECRETASE BACE1 CONTROLS SYNAPTIC STRENGTH IN THE MURINE BRAIN
LiebschFilipCanadaC-TERMINALLY TRUNCATED ABETA-SPECIES IN THE CSF OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND PRE-SYMPTOMATIC ALZHEIMER DISEASE
LinChin-HsienTaiwanLOVASTATIN PROTECTS NEURITE DEGENERATION IN LRRK2-G2019S PARKINSONISM THROUGH ACTIVATING THE AKT/NRF PATHWAY AND INHIBITING GSK3ΒETA ACTIVITY
LipsmeierFlorianSwitzerlandREMOTE, HIGH-FREQUENCY MONITORING OF MOTOR SYMPTOMS IN EARLY-STAGE PARKINSON’S DISEASE PATIENTS IN THE PHASE I RG7935/PRX002 CLINICAL TRIAL
LiptonStuartUSAREDOX-MEDIATED LINK BETWEEN ALZHEIMER’S DISEASE AND TYPE 2 DIABETES WITH THERAPEUTIC IMPLICATIONS
LleoAlberto SpainCEREBRAL AMYLOID ANGIOPATHY IN DOWN SYNDROME, AUTOSOMAL DOMINANT AND SPORADIC ALZHEIMER´S DISEASE
LobbestaelEvyBelgiumPHARMACOLOGICAL LRRK2 KINASE INHIBITION INDUCES LRRK2 PROTEIN DESTABILIZATION AND PROTEASOMAL DEGRADATION
LogsdonBenjaminUSATRANSCRIPTOMIC NETWORK PRIORITIZATION OF ALZHEIMER’S DISEASE DRIVERS
LombardoIliseUSAPHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES: THE HEADWAY-DLB STUDY
LongoFrankUSAAN ORALLY BIOAVAILABLE SMALL MOLECULE P75 RECEPTOR LIGAND INHIBITS TAU MOLECULAR PATHOLOGY
LongoniMartinaItalyVALIDATION OF CSF ANTI-AΒ AUTOANTIBODIES AND TISSUE FACTOR PATHWAY INHIBITOR AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS OF CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION
LowWalterUSATOWARDS THE GENERATION OF NIGRAL DOPAMINE NEURONS IN GENE EDITED ANIMALS VIA STEM CELL COMPLEMENTATION FOR TREATING PARKINSON DISEASE
LukiwWalter J.USAMICRORNA (MIRNA) SIGNALING IN ALZHEIMER'S DISEASE (AD)
LundgrenJolanta L.SwedenSYNAPTIC LOCALIZATION OF ADAM10 AND BACE1 IN ADULT RAT AND HUMAN BRAIN
MaccecchiniMariaUSATREATING ACUTE AND CHRONIC NEURODEGENERATION BY INHIBITING NEUROTOXIC AGGREGATING PROTEINS
MajidOneebUnited KingdomE2609, A NOVEL BACE INHIBITOR DEMONSTRATES PROOF-OF-PHARMACOLOGY IN CSF AND PLASMA IN MCI DUE TO AD AND MILD-MODERATE AD DEMENTIA
MandelkowEckhardGermanyTAU FOLDING, MISFOLDING, AND PROPAGATION
MandelkowEva-MariaGermanyANIMAL MODELS OF TAU PATHOLOGY - TOXICITY WITH OR WITHOUT AGGREGATION
ManfredssonFredricUSANIGROSTRIATAL OVEREXPRESSION OF ALPHA-SYNUCLEIN INDUCES NEURODEGENERATION VIA A TOXIC LOSS OF FUNCTION MECHANISM
MarcelloElenaItalyCYCLASE-ASSOCIATED PROTEIN 2 (CAP2) CROSSING ALZHEIMER DISEASE PATHOGENESIS PATHWAYS: AMYLOID GENERATION AND ACTIN-DEPENDENT DENDRITIC SPINES SHAPING
MarchettiBiancaItalyADULT STEM/NEUROPROGENITORS TRANSPLANTED IN PARKINSONIAN MOUSE SUBTANTIA NIGRA TRIGGER AN ASTROCYTE-DEPENDENT DOPAMINERGIC NEURORESTORATION: A CHIEF ROLE FOR WNT/BETA-CATENIN SIGNALING NETWORK
MarekKenUSASTRATEGIES TO IDENTIFY PARKINSON DISEASE PROGRESSION SUBSETS - THE PPMI STUDY
MarizzoniMoiraItalyEFFECT OF APOE GENOTYPE ON PATHOLOGICAL CEREBROSPINAL FLUID CUT-POINTS IN MILD COGNITIVE IMPAIRMENT
MaroofNaziaSwitzerlandSEVERITY OF INFLAMMATION MODULATES EXTENT OF ALPHA-SYNUCLEIN ACCUMULATION IN THE ENTERIC NERVOUS SYSTEM
MarquesTaináThe NetherlandsMICRORNAS IN CEREBROSPINAL FLUID AS POTENTIAL BIOMARKERS FOR PARKINSON’S DISEASE AND MULTIPLE SYSTEM ATROPHY
MarshSamuelUSAAMYLOID AND TAU PATHOLOGY INDUCE SIGNIFICANT T CELL INFILTRATION IN MOUSE MODELS OF ALZHEIMER’S DISEASE
MartinezAnaSpainREGULATION OF TDP-43 PATHOLOGY BY CDC-7 INHIBITORS TREATMENT
MaruffPaulAustraliaSENSITIVITY OF THE ALZHEIMER DISEASE COOPERATIVE STUDY PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE (ADCS-PACC),TO AMYLOID LOAD IN PRECLINICAL AD
MastersColinAustraliaTARGETING THE DYNAMICS OF ABETA AMYLOID PRODUCTION/CLEARANCE IN SPORADIC ALZHEIMER’S DISEASE
MatroneCarmelaDenmarkABNORMAL HYPERPHOSPHORYLATION OF TYROSINE RESIDUES ALTERS APP ENDOCYTOSIS IN NEURONS FROM ALZHEMER'S  DISEASE AFFECTED PATIENTS.
MatsumotoYohJapanDEVELOPMENT OF THIRD-GENERATION DNA VACCINES TARGETING A WIDE RANGE OF AMYLOID-BETA AND TAU PEPTIDES IN ALZHEIMER’S DISEASE
MattssonNiklasSwedenTAU PATHOLOGY MEASURED BY 18F-AV1451 PET AND CSF BIOMARKERS IN ALZHEIMER'S DISEASE
MayeuxRichardUSAWHOLE EXOME AND WHOLE GENOME SEQUENCING IN CARIBBEAN HISPANICS FAMILIES
McAleeseKirstyUnited KingdomWHITE MATTER LESIONS IN ALZHEIMER'S DISEASE HAVE SIGNIFICANTLY MORE AXONAL LOSS COMPARED TO WHITE MATTER LESIONS IN AGEING
McLaurinJoAnneCanadaVASCULAR AND NEURONAL COMPROMISE IN TGF344 AD RAT MODEL OF ALZHEIMER’S DISEASE
McMillanCoreyUSACONVERGING EVIDENCE FOR GENETIC RISK FACTORS OF ALPHA-SYNUCLEIN PATHOLOGY IN ALZHEIMER’S DISEASE
MendoncaNunoGermanyCOMPARISON OF BIOMARKERS BETWEEN A PHASE 0 STUDY IN ALZHEIMER'S DISEASE AND THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE LONGITUDINAL COHORT
MeziasChristopherUSAAD-LIKE SPATIOTEMPORAL TAU PATHOLOGY SPREAD, IN MOUSE MODELS, EXHIBITS A RETROGRADE BIAS AND IMPLIES DISEASE INITIATION LOCATION IS RANDOM
MichaelsonDaniel M.IsraelTHE ROLE OF HYPOLIPIDATION IN MEDIATING THE PATHOLOGICAL EFFECTS OF APOE4
MielkeMichelleUSAPLASMA CERAMIDE TO GLUCOSYLCERAMIDE RATIO IS ASSOCIATED WITH PARKINSON’S DISEASE (PD) SEVERITY AND PREDICTS COGNITIVE DECLINE AMONG COGNITIVELY NORMAL PD PATIENTS WITHOUT GBA MUTATIONS
MoecharsDiederikBelgiumTRANSSYNAPTIC SPREADING OF TAU PATHOLOGY IS MODULATED BY BIN1, A GENETIC RISK FACTOR FOR LATE ONSET ALZHEIMER`S DISEASE
MoirRobertUSAROLE OF OLIGOMERS AND HOST CYTOTOXICITY IN THE ANTIMICROBIAL PEPTIDE ACTIONS OF ABETA
Mook-JungInheeRepublic of KoreaTHE ROLE OF MITOCHONDRIA IN ALZHEIMER'S DISEASE PATHOGENESIS
MoralesRodrigoUSAPERIPHERAL AMYLOID-BETA SEEDS AS EFFICIENT INDUCERS OF BRAIN AMYLOIDOSIS AND CEREBRAL AMYLOID ANGIOPATHY
MorganDavidUSADRAMATIC METABOLIC CHANGES IN A MOUSE MODEL OF TAU DEPOSITION AND THE  IMPACT OF METABOLIC THERAPY
MorizaneAsukaJapanCELL THERAPY FOR PARKINSON’S DISEASE WITH INDUCED PLURIPOTENT STEM CELLS
MufsonElliottUSAALZHEIMER'S DISEASE PATHOLOGY IN NON-COGNITIVELY IMPAIRED ELDERS : A ROLE FOR COGNITIVE RESERVE
MüllerUlrikeGermanyASSESSING THE THERAPEUTIC POTENTIAL OF SAPPALPHA: RESCUE OF SYNAPTIC DYSFUNCTION IN ALZHEIMER MODEL MICE AND CONDITIONAL APP/APLP2 DOUBLE KNOCKOUT MICE
MulthaupGerhardCanadaAPLP1 IS CLEAVED BY Γ-SECRETASE WITHOUT PREVIOUS ECTODOMAIN SHEDDING
MunterLisaCanadaALTERNATIVE PROCESSING OF APP BY A RHOMBOID PROTEASE
MuresanVirgilUSAA NEURONAL CULTURE MODEL FOR SPORADIC ALZHEIMER’S DISEASE WITH AMYLOID-Β (AΒ) AND TAU PATHOLOGY, IN THE ABSENCE OF FAD MUTATIONS
MurrayMelissaUSAUTILIZATION OF QUANTITATIVE DIGITAL PATHOLOGY AND RNA-SEQUENCING TO UNCOVER MOLECULAR UNDERPINNINGS OF SELECTIVE HIPPOCAMPAL VULNERABILITY IN ALZHEIMER’S DISEASE VARIANTS
NestorPeter J.GermanyTHE LANDSCAPE OF BRAIN IRON DYSREGULATION IN EARLY PARKINSON’S DISEASE
NeumannManuelaGermanyC9ORF72 EXPRESSION IN HEALTH AND DISEASE
NeumannUlfSwitzerlandEFFECT OF BACE INHIBITION ON NEUROINFLAMMATION, NEURODEGENERATION AND NEURONAL NETWORK ALTERATIONS IN APP-TRANSGENIC MOUSE MODELS
NickelsSarahLuxembourgSYSTEMIC ANALYSIS OF GENOME-WIDE REGULATIONS IN HUMAN NEUROEPITHELIAL STEM CELLS CARRYING LRRK2-G2019S
NicolasGaëlFranceTHE UNSUSPECTED ROLE AND FREQUENCY OF DE NOVO MUTATIONS IN SPORADIC EARLY ONSET ALZHEIMER DISEASE
NilsonAshleyUSATHE MECHANISM OF BRAIN-DERIVED TAU OLIGOMER INTERNALIZATION IN PRIMARY NEURONS
NilssonPerSwedenSOMATOSTATIN RECEPTOR 1 AGONIST TREATMENT LOWERS AMYLOID BETA PATHOLOGY IN APP-KNOCK-IN MOUSE MODEL
NixonRalphUSAIN VIVO AUTOPHAGY REPORTER DETECTS AUTOLYSOSOME DYSFUNCTION IN NEURONS WELL BEFORE EXTRACELLULAR AMYLOID DEPOSITION IN ALZHEIMER’S DISEASE (AD) MOUSE MODELS
NobleElizabethUnited KingdomCHARACTERISING OLIGOMERIC AMYLOID-BETA IN MOUSE MODELS OF ALZHEIMER’S DISEASE
NorambuenaAndresUSANADH FLUORESCENT LIFE TIME MICROSCOPY IN LIVE NEURONS UNVEILS A NOVEL LYSOSOME TO MITOCHONDRIA SIGNALING PATHWAY DISRUPTED IN ALZHEIMER'S DISEASE
NordbergAgnetaSwedenREGIONAL TAU DEPOSITION IN THE EVOLUTION OF ALZHEIMER´S DISEASE IN RELATION TO AMYLOID AND INFLAMMATION AS STUDIED BY MULTI-TRACER PET
NuberSilkeUSASHIFTING MULTIMERS: NEW MOUSE AND CULTURE MODELS OF ALPHA-SYNUCLEIN TRUNCATION BY CALPAIN IN PARKINSON'S DISEASE
OddoSalvatoreUSAMECHANISMS OF NEURONAL LOSS IN ALZHEIMER’S DISEASE
OecklPatrickGermanyALPHA-, BETA- AND GAMMA-SYNUCLEIN QUANTIFICATION IN CSF BY HIGHLY SELECTIVE MASS-SPECTROMETRY REVEALS INCREASED CONCENTRATIONS IN ALZHEIMER´S AND CREUTZFELDT-JAKOB DISEASE BUT NO ALTERATION IN SYNUCLEINOPATHIES
OffenDanielIsraelA NOVEL CASPASE-6 INHIBITOR AS A POTENTIAL THERAPY FOR ALZHEIMER'S DISEASE
OlahMartaUSAMICROGLIA IDENTITY IN THE AGED HUMAN BRAIN
OlofssonAndersSwedenTHE DETERMINANTS CONTROLLING AMYLOID BETA FIBRIL FORMATION
OrrMirandaUSAALZHEIMER’S  DISEASE  ASSOCIATED  TAU  PATHOLOGY INDUCES  CELLULAR  SENESCENCE  IN  BRAIN
OstenfeldThorUnited KingdomSAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA-AMYLOID 42-SPECIFIC ANTIBODY, IN MILD-MODERATE ALZHEIMER'S DISEASE
OteroKarelUSATREM2 IS A CORECEPTOR OF THE MACROPHAGE/MICROGLIA GROWTH FACTOR RECEPTOR CSF-1R
PaillussonSébastienUnited KingdomALPHA-SYNUCLEIN BINDS TO THE ER-MITOCHONDRIA TETHERING PROTEIN VAPB TO DISRUPT CA2+ HOMEOSTASIS AND MITOCHONDRIAL ATP PRODUCTION
PalmqvistSebastianSwedenTHE STARTING REGIONS OF AMYLOID-Β ACCUMULATION IN ALZHEIMER’S DISEASE
PaquetDominikGermanyA CRISPR/CAS9-BASED GENE EDITING FRAMEWORK ALLOWS MODELING EARLY-ONSET ALZHEIMER’S DISEASE IN GENETICALLY DEFINED HUMAN IPSC LINES
ParkkinenLauraUnited KingdomALPHA-SYNUCLEIN RT-QUIC IN THE CSF OF PATIENTS WITH ALPHA-SYNUCLEINOPATHIES - A NEW POTENTIAL DIAGNOSTIC MARKER
PasternakStephenCanadaTREATING DEMENTIA WITH COUGH MEDICINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL REPUPOSING AMBROXOL AS A NOVEL DISEASE MODIFYING TREATMENT FOR PARKINSON’S DISEASE DEMENTIA
PatraKalicharanSwedenPLASMA LEVELS OF KALLIKREIN-LIKE PROTEASE 6 ARE INCREASED IN PATIENTS WITH ALZHEIMER’S DISEASE AND APPEAR TO BE ASSOCIATED WITH APOEΕ4 STATUS
PaulBinduUSAINTERSECTION OF AMINO ACID METABOLISM AND REDOX HOMEOSTASIS IN HUNTINGTON’S DISEASE
PaulsEduardoSpainNEW CELLULAR MODELS TO STUDY ALZHEIMER'S DISEASE USING CRISPR/CAS9 TECHNOLOGY
Pericak-VanceMargaretUSAFAMILY-BASED ANALYSES OF WHOLE GENOME SEQUENCING IN WHITE, NON-HISPANIC POPULATIONS
PetersOliverGermanyINTERRELATIONSHIP OF BETA AMYLOID RATIO 42/40 AND TTAU AND ITS DEPENDENCY ON APOE GENOTYPE
PiazzaFabrizioItalyTHE ARIA PARADOX: OFF-KEY OR KEYNOTE IN THE OPERA OF IMMUNOTHERAPY?
PiniLorenzoItalyNON-INVASIVE INTERVENTION IN ALZHEIMER’S DISEASE WITH TRANSCRANIAL DIRECT CURRENT STIMULATION
PlanelEmmanuelCanadaSPINAL CHORD INJURY INDUCES TAU PATHOLOGY IN THE BRAIN
PoeweWernerAustriaCURRENT DEVELOPMENTS IN THE TREATMENT OF PARKINSON’S DISEASE - FROM DISEASE MODIFICATION TO PREVENTION?
PolymenidouMagdaliniSwitzerlandDYNAMIC POLYMERIZATION OF TDP-43 IN HEALTH AND DISEASE
PoppJuliusSwitzerlandMACROPHAGE MIGRATION INHIBITORY FACTOR IS ASSOCIATED WITH BIOMARKERS OF ALZHEIMER’S DISEASE PATHOLOGY AND PREDICTS COGNITIVE DECLINE IN MCI AND MILD DEMENTIA.
PostonKathleenUSADOUBLE DISSOCIATION BETWEEN DEFAULT MODE NETWORK CONNECTIVITY AND ABNORMAL CSF BETA-AMYLOID AND PHOSPHORYLATED TAU IN PARKINSON’S DISEASE
PradoMarcoCanadaCHOLINERGIC REGULATION OF RNA METABOLISM, COGNITION AND ALZHEIMER’S PATHOLOGY
PrasadVibhaGermanyASSESSMENT OF ALPHA-SYNUCLEIN AGGREGATION AND TRANSMISSION IN VIVO
PrashantBharadwajAustraliaTHE BETA AMYLOID-AMYLIN INTERACTION: IS THERE A MOLECULAR LINK BETWEEN DIABETES AND ALZHEIMER’S DISEASE?
PraticoDomenicoUSAA NOVEL ROLE FOR CASPASE-3 AS MODULATOR OF TAU PHOSPHORYLATION: IMPLICATIONS FOR ALZHEIMER’S DISEASE AND RELATED TAUOPATHIES
ProkopenkoIngaUnited KingdomASSOCIATION OF DEMENTIA WITH LEWY BODIES WITH APOE-Ɛ4/TOMM40 LONG POLY-T REPEAT IS DUE TO CO-EXISTING ALZHEIMER’S DISEASE PATHOLOGY
Raha-ChowdhuryRumaUnited KingdomNEUROPROTECTIVE EFFECT OF TREM-2 IN ALZHEIMER’S DISEASE AND DOWN’S SYNDROME
RahimipourShaiIsraelTARGETING THE TOXIC OLIGOMERS OF AMYLOIDOGENIC PROTEINS BY SELF-ASSEMBLED CYCLIC D,L-ALPHA-PEPTIDES: POTENTIAL APPLICATION FOR ALZHEIMER’S AND PARKINSON’S DISEASES
RajendranLawrenceSwaziland DESIGNING SAFER BETA-SECRETASE INHIBITORS FOR ALZHEIMER’S DISEASE THERAPY
RakezKayedUSATARGETING DISEASE-SPECIFIC TAU OLIGOMERS BY IMMUNOTHERAPY
RanumLauraUSAREPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION IN NEUROLOGIC DISEASE: LESSONS FROM C9ORF72 ALS/FTD BAC MICE
ReedXylenaUSABAG3 IS A CANDIDATE GENE FOR INCREASED RISK OF SPORADIC PARKINSON’S DISEASE
RektorovaIrenaCzech RepublicFUNCTIONAL CONNECTIVITY PATTERNS IN AD AND PD: LESSONS FROM LONGITUDINAL STUDIES
RemnestålJuliaSwedenPROTEIN PROFILING IN CSF AND PLASMA REVEALS ASSOCIATIONS OF SYNAPTIC PROTEINS NEUROMODULIN AND NEUROGRANIN TO ALZHEIMER’S DISEASE
RiekRolandSwitzerlandSTRUCTURE-ACTIVITY RELATIONSHIPS OF AB(1-42) AMYLOID AND A-SYNUCLEIN MULTIMERS IN AD AND PD
RiesMiriamUnited KingdomTHE ANTI-INFLAMMATORY ANNEXIN A1 AMELIORATES BLOOD BRAIN BARRIER DISRUPTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE
RisacherShannonUSADIFFERENTIAL ATROPHY PATTERNS IN PARKINSON’S DISEASE WITH COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE WITH PARKINSONIAN SYMPTOMS
RobakisNikosUSAFAD MUTANTS INCREASE NEURODEGENERATION BY FORMING TOXICITY-SENSITIVE PROTEIN COMPLEXES AND BLOCKING NEUROTROPHIN-DEPENDENT NEUROPROTECTION
RobertsJillUSAEARLY CHANGES IN THE EXTRACELLULAR MATRIX AND BLOOD-BRAIN BARRIER INTEGRITY FOLLOWING MOUSE BILATERAL CAROTID ARTERY STENOSIS
RongveArvidNorwayGENOME WIDE ASSOCIATION STUDY IN LEWY BODY DEMENTIA
RosenzweigNetaIsraelTHERAPUTIC EFFECT OF PD-1 IMMUNE CHECKPOINT BLOCKADE IN TAU AND AMYLOID-BETA MOUSE MODELS OF ALZHEIMER’S DISEASE
RossorMartin N.United KingdomWHAT CAN WE LEARN FROM THE TREATMENT OF SYSTEMIC AMYLOIDOSES?
RoussotteFlorenceUSAIN VIVO PLAQUE AND TANGLE BURDEN MEDIATES THE ASSOCIATION BETWEEN DIASTOLIC BLOOD PRESSURE AND COGNITIVE PERFORMANCE IN NON-DEMENTED OLDER ADULTS
Rovelet-LecruxAnneFranceWHOLE EXOME SEQUENCING IN 522 EARLY-ONSET ALZHEIMER PATIENTS REVEALS MAPT DUPLICATIONS AS A CAUSE OF PROMINENT TAU-RELATED DEMENTIA WITH INCREASED MAPT EXPRESSION
RyazantsevaMariaRussiaATTENUATED PRESENILIN-1 ENDOPROTEOLYSIS LEADS TO STIM1 GAIN-OF-FUNCTION AND ENHANCED ACTIVATION OF ORAI AND TRPC CHANNELS
Saez-ValeroJavierSpainSOLUBLE COMPLEXES OF PRESENILIN-1 IN ALZHEIMER’S CEREBROSPINAL FLUID AS AN ASYMPTOMATIC BIOMARKER
SaidoTakaomiJapanIDENTIFICATION AND CHARACTERIZATION OF ABETA PATHOLOGY-DEPENDENT TAU-BINDING PROTEINS
SaltaEvgeniaBelgiumMIR-132: USING NEUROGENESIS TO FIGHT NEURODEGENERATION IN ALZHEIMER’S DISEASE
SamieriCéciliaFranceNUTRIENT BIOMARKER PATTERNS AND RISK OF DEMENTIA
Sanabria DiazGretelSwitzerlandAPOE*E4 IMPACT ON THE CORTICAL THICKNESS BRAIN NETWORKS TOPOLOGY IN MILD COGNITIVE IMPAIRMENT
SandbergAndersSwedenTHIRD GENERATION IMMUNOTHERAPY FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
SannerudRagnaBelgiumRESTRICTED LOCATION OF PSEN2/Γ-SECRETASE DETERMINES SUBSTRATE SPECIFICITY AND GENERATES AN INTRACELLULAR AΒ POOL
SardiPabloUSATARGETING LYSOSOMAL GLUCOCEREBROSIDASE DEFECTS IN THE TREATMENT OF PARKINSON’S DISEASE: FROM GENETICS TO THERAPEUTICS
SargeantTimAustraliaMTOR REGULATES TRAFFICKING OF AMYLOID PRECURSOR PROTEIN TO THE LYSOSOME
SavonenkoAlenaUSACLEARANCE OF NEURONAL AND ASTROCYTIC ABETA AND CEREBRAL AMYLOID ANGIOPATHY
SchapiraAnthonyUnited KingdomGBA CHAPERONES IN CELL AND ANIMAL MODELS OF GBA-PD; PROSPECTS FOR TREATMENT
SchellenbergGerardUSALARGE-SCALE DNA SEQUENCE ANALYSIS AND ALZHEIMER’S DISEASE GENETICS
ScheltensPhilipThe NetherlandsCAN’T SEE THE WOOD FOR THE TREES? A QUICK GUIDE THROUGH ALL THE NEW CRITERIA FOR AD
SchemmertSarahGermanyTHERAPEUTIC TREATMENT WITH A D-ENANTIOMERIC PEPTIDE IMPROVES COGNITIVE IMPAIRMENT IN AGED APPSWE/PS1 TRANSGENIC MICE
SchmidtReinholdAustriaIMAGING OF CEREBRAL SMALL VESSEL DISEASE
SchmittKarenSwitzerlandDISRUPTED BIOLOGICAL CLOCK LINKED TO AMYLOID-Β-INDUCED IMBALANCE IN MITOCHONDRIAL NETWORK.
SchmitzTaylorUnited KingdomBASAL FOREBRAIN DEGENERATION PRECEDES AND PREDICTS THE CORTICAL SPREAD OF ALZHEIMER'S PATHOLOGY
SchöllMichaelSwedenEARLY- AND LATE-ONSET ALZHEIMER’S DISEASE SHOW DISTINCT TAU PATHOLOGY AS EXAMINED WITH 18F-AV-1451 TAU POSITRON EMISSION TOMOGRAPHY
SchwartzMichalIsraelHARNESSING SYSTEMIC IMMUNITY TO FIGHT NEURODEGENERATIVE DISEASES: THE POTENTIAL OF IMMUNE CHECKPOINT BLOCKADE FOR FIGHTING AGAINST ALZHEIMER'S DISEASE
SegalMenachemIsraelCALCIUM STORES IN ANIMAL MODELS OF AD
SehlinDagSwedenEFFICIENT CLEARANCE OF ABETA PROTOFIBRILS IN APP-TRANSGENIC MICE TREATED WITH A BRAIN PENETRATING BIFUNCTIONAL ANTIBODY
SelkoeDennisUSAALPHA-SYNCULEIN MULTIMER-MONOMER EQUILIBRIA AND THE INITIATION OF PARKINSON'S DISEASE
SelnesPerNorwaySYNAPTIC FUNCTION AND INTEGRITY IS LINKED TO COGNITION IN PARKINSON'S DISEASE
ShamsSaraSwedenMICROINFARCTS DETECTED ON MRI – ANOTHER IMPORTANT IMAGING BIOMARKER IN COGNITIVE IMPAIRMENT?
SharonRonitIsraelALPHA -SYNUCLEIN LEVELS IN HUMAN BLOOD CELLS, CSF AND SALIVA DETERMINED BY  A LIPID-ELISA: A BIOMARKER FOR PARKINSON’S DISEASE
ShenJieUSAPRESENILIN IN HEALTH AND ALZHEIMER’S DISEASE
SherEmanueleUnited KingdomHYPER-PHOSPHORYLATED, AGGREGATED AND SEEDING COMPETENT TAU IN RODENT AND HUMAN SYNAPTOSOMES
ShiihashiGenJapanNOVEL ALS/FTD MODEL MICE EXPRESSED CYTOPLASMIC FUS IN A TOXIC GAIN-OF-FUNCTION MANNER
ShimizuSoichiroJapanCORRELATION BETWEEN CLINICAL SYMPTOMS AND STRIATAL DAT UPTAKE IN PATIENTS WITH DLB.
ShoaiMaryamUnited KingdomIDENTIFICATION OF AMYLOID POSITIVE INDIVIDUALS IN MCI OR ELDERLY PRE-SYMPTOMATIC COHORTS USING A NOVEL PANEL
ShulmanJoshuaUSAEXCESSIVE BURDEN OF LYSOSOMAL STORAGE DISORDER GENE VARIANTS IN PARKINSON’S DISEASE
ShutinoskiBojanCanadaLEUCINE-RICH REPEAT KINASE-2 (LRRK2) ALLELES REGULATE INFLAMMATION IN VIRULENT INFECTION MODELS
SilvaJoanaPortugalTHE “STRESSED” AUTOPHAGY: CHRONIC STRESS EXACERBATES TAU PATHOLOGY BY BLOCKING AUTOPHAGY CLEARANCE SYSTEM
SimonovitchShiraIsraelAPOE4 IMPAIRS AUTOPHAGY IN NEURONS
SisodiaSangram S.USATHE ROLE OF THE MICROBIOME IN MODULATION OF AMYLOID DEPOSITION
SmallDavid H.AustraliaTHE ROLE OF APP IN ALZHEIMER’S DISEASE NEXOPATHY:  AN ALTERNATIVE TO THE PRION HYPOTHESIS
SmrzkaOskarAustriaIN VITRO AND IN VIVO FUNCTIONAL EVALUATION OF ANTIBODY-BASED HUNTINGTIN TARGETING STRATEGIES.
SnaedalJonIcelandRETINAL OXYGEN METABOLISM IN ALZHEIMER´S DISEASE
SnyderPeterUSADISRUPTION OF CHOLINERGIC NEUROTRANSMISSION IN PRECLINICAL ALZHEIMER’S DISEASE: NOVEL BIOMARKERS FOR EARLY DETECTION
SoininenHilkkaFinlandTHE LIPIDIDIET TRIAL - EFFECTS OF FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE
SolomonBekaIsraelCHRONIC ADMINISTRATION OF AMD 3100  AS A MULTIFACETED THERAPEUTIC STRATEGY FOR TREATMENT OF NEURODEGENERATION
SoreqHermonaIsraelINTER-RELATED RNA AND LIPID PROCESSING CHANGES IN COGNITIVELY DECLINED ALZHEIMER’S BRAINS
SotiropoulosIoannisPortugalTAU PROTEIN IS ESSENTIAL FOR STRESS-DRIVEN DEPRESSIVE PATHOLOGY AND COGNITIVE DEFICITS
SotoClaudioUSACYCLIC AMPLIFICATION OF PROTEIN MISFOLDING FOR SENSITIVE DIAGNOSIS OF ALZHEIMER'S AND PARKINSON'S DISEASES
SpäniClaudiaUSAAN ALZHEIMER’S DISEASE MOUSE MODEL LACKING FUNCTIONAL ADAPTIVE IMMUNE CELLS SHOWS REDUCED AMYLOID PATHOLOGY, ALTERED MICROGLIAL RESPONSES AND REDUCED SURVIVAL
SperlingReisaUSAEVOLUTION OF PRECLINICAL ALZHEIMER’S DISEASE: IMPLICATIONS FOR PREVENTION TRIALS
SpillantiniMaria GraziaUnited KingdomDOPAMINERGIC DYSFUNCTION AND NEURONAL DEATH IN A NEW A-SYNUCLEIN TRANSGENIC MODEL IS RESCUED BY ANLE138B BY AFFECTING A-SYNUCLEIN AGGREGATES DENSITY
St. George-HyslopPeterCanadaEFFECT OF THE AD-RELATED TREM2 R47H MUTATION ON TREM2 FUNCTION
SteenJudithUSATAU CHEMISTRY IS DISTINCT FOR ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES
SteenHannoUSAGLOBAL ANALYSIS OF TAUOPATHY PATIENTS IDENTIFIES BOTH COMMON AND SPECIFIC DISEASE PATHWAYS
StefanovaNadiaAustriaTARGETING ALPHA-SYNUCLEIN PATHOLOGY WITH THE MOLECULAR TWEEZER CLR01 IN MULTIPLE SYSTEM ATROPHY
StephensAndrewUSACHARACTERIZATION OF NOVEL PET TRACERS FOR THE ASSESSMENT OF TAU PATHOLOGY IN ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES
StevensBethUSAIMMUNE MECHANISMS OF SYNAPSE LOSS IN AD: LESSONS FROM DEVELOPMENT
StrefferJohannesBelgiumINTERACTION OF TAU AND AMYLOID PATHOLOGY IS RELEVANT FOR COGNITIVE CHANGES. MOVING THE AMYLOID CASCADE HYPOTHESIS TO AN INTERACTION MODEL?
StrosznajderJoannaPolandINTERFERENCE BETWEEN PARP-1 AND SIRTUINS: THE ROLE IN REGULATION OF GENE EXPRESSION AND MITOCHONDRIA FUNCTION IN MODEL OF ALZHEIMER’S DISEASE
StutzmannGraceUSAEARLY SYNAPTIC DEFICITS IN AD PATHOGENESIS
SüdhofThomasUSAAPOE, SYNAPSES, AND ALZHEIMER’S DISEASE
SuhYoo-HunRepublic of KoreaINVOLVEMENT OF 14-3-3 IN TUBULIN INSTABILITY AND IMPAIRED AXON DEVELOPMENT MEDIATED BY TAU
SuhJaehongUSADEPLETION OF ATAXIN-1 INCREASES BACE1 EXPRESSION AND IMPAIRS AXON GUIDANCE IN CEREBRUM
Suter-DickLauraSwitzerlandA THREE-DIMENSIONAL, HUMAN CO-CULTURE MODEL FOR THE STUDY OF MECHANISMS IN ALZHEIMER'S DISEASE
SyvänenStinaSwedenANTIBODY-BASED PET RADIOLIGANDS FOR IMAGING OF AMYLOID-BETA PROTOFIBRILS
TagaMarikoUSASTUDY OF CD33: AN ALZHEIMER’S DISEASE SUSCEPTIBILITY LOCUS IN NEURODEGENERATION
TakenoshitaNaotoJapanCOMPARISON OF DIAGNOSTIC UTILITY OF SEMI-QUANTITATIVE ANALYSIS FOR DAT-SPECT FOR DISTINGUISHING DLB FROM AD
TamgüneyErdem GültekinGermanyΑLPHA-SYNUCLEIN PRIONOIDS NEUROINVADE THE CNS AFTER PERIPHERAL INJECTION
TanziRudolphUSAMODELING ALZHEIMER’S DISEASE IN THE WHOLE GENOME ERA
TaylorGraemeCanadaDISRUPTIONS IN LAND’S CYCLE REMODELLING OF MEMBRANE GLYCEROPHOSPHOCHOLINES ARE A DEFINING ALZHEIMER’S DISEASE PATHOLOGY
Tba  HETEROMERIZATION  OF M1 MUSCARINC/SIGMA1 RECEPTORS AS A UNIQUE  AD THERAPEUTIC TARGET
TcwJuliaUSAAN EFFICIENT PLATFORM FOR ASTROCYTE DIFFERENTIATION FROM HUMAN INDUCED PLURIPOTENT STEM CELLS: APPLICATION TO APOE GENOTYPE SPECIFIC EFFECTS ON GENE EXPRESSION AND FUNCTION
TeunissenCharlotteThe NetherlandsNOVEL CSF BIOMARKERS DISCRIMINATING FTLD-TDP FROM NON-DEMENTED CONTROLS
ThalDietmarBelgiumCEREBRAL AMYLOID ANGIOPATHY, MICROINFARCTION AND THE DEVELOPMENT OF DEMENTIA.
ThalerAvnerIsraelGAIT IN HEALTHY CARRIERS AND NON-CARRIERS OF MUTATIONS IN THE GBA GENE: POTENTIAL CLINICAL MARKERS OF DISEASE
ThierryManonFranceTHE ROLE OF AXONS IN THE PROPAGATION OF THE LESIONS IN ALZHEIMER'S DISEASE: A STUDY OF THE PILLAR OF THE FORNIX
TodaTatsushiJapanASSOCIATION STUDY OF PARKINSON’S DISEASE BY SNP AND EXOME SEQUENCING
TofarisGeorgeUnited KingdomSEEDED AGGREGATION OF Α-SYNUCLEIN INDUCES A DISTINCT PATTERN OF UBIQUITIN PERTURBATIONS IN HUMAN CELLS
TothGergelyHungaryMONOMERIC ALPHA-SYNUCLEIN INTERACTS THROUGH ITS N-TERMINAL WITH DJ-1 PROTEIN OXIDIZED AT CYS106:  IMPLICATIONS FOR OF ALPHA-SYNUCLEIN AGGREGATION INHIBITION BY DJ-1
TousiBabakUSAEFFECTS OF A COMBINED TRANSCRANIAL MAGNETIC STIMULATION (TMS) AND COGNITIVE TRAINING IN ALZHEIMER PATIENTS: SAFETY RESULTS OF MEDICAL DEVICE PIVOTAL MULTI-CENTER STUDY
TrabzuniDaniahUnited KingdomCHARACTERIZING GENE EXPRESSION AND SPLICE ISOFORMS OF LRRK2 IN HUMAN BRAIN: TOOLS FOR UNDERSTANDING COMPLEX NEURODEGENERATIVE DISEASES
Tran ZhaoHienUSAANTISENSE OLIGONUCLEOTIDES TO LRRK2 AMELIORATE ALPHA-SYNUCLEIN PATHOLOGY AND BEHAVIORAL DEFICIT INDUCED BY PRE-FORMED ALPHA-SYNUCLEIN FIBRILS
TrojanowskiJohn Q.USAINTERACTIONS OF HUMAN ALZHEIMERS DISEASE (AD) BRAIN DERIVED PATHOLOGICAL TAU (AD-TAU) WITH AΒ DEPOSITS IN AMYLOID PRECURSOR PROTEIN TRANGENIC AND KNOCK IN (KI) MICE
TronelClaireFranceSIMVASTATIN, BUT NOT ATORVASTATIN, HAS ANTI-INFLAMMATORY AND NEUROPROTECTIVE EFFECTS IN AN IN VIVO RAT MODEL OF HUNTINGTON DISEASE
TwohigDanielSwedenCEREBROSPINAL FLUID LEVELS OF ALPHA-SYNUCLEIN ARE RELATED TO DISEASE PROGRESSION AND APOEΕ4 GENOTYPE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT
TyagiRichaUSAROLE OF INOSITOL PHOSPHATE SIGNALING PATHWAY IN ALZHEIMER’S DISEASE
Udeh-MomohChineduUnited KingdomTHE CHARIOT COGNITIVE RESERVE COMPOSITE: A CONSTRUCT AND PREDICTIVE VALIDITY STUDY
UgrumovMichaelRussiaDOPAMINE SYNTHESIS BY STRIATAL NON-DOPAMINERGIC NEURONS: HITHERTO UNKNOWN MECHANISM OF NEUROPLASTICITY AT PARKINSONISM
UmanskySamuilUSACIRCULATING BRAIN-ENRICHED MICRORNAS AS BIOMARKERS OF NEURODEGENERATIVE DISEASES
UmedaTomohiroJapanTHE OSAKA MUTATION KNOCKIN MICE SHOW RECESSIVE HEREDITARY DEMENTIA VIA GABAERGIC DEPLETION
UnschuldPaul G.SwitzerlandTRACKING PATHOLOGY ASSOCIATED WITH PRECLINICAL BRAIN CHANGE IN SUBJECTS AT RISK FOR AD
Van BroeckhovenChristineBelgiumPROGRESS IN UNRAVELLING THE GENETICS OF EARLY-ONSET DEMENTIA
Van DamAnne-MarieThe NetherlandsEARLY MICROGLIAL ACTIVATION BEYOND THE SUBSTANTIA NIGRA IN PARKINSON’S DISEASE
Van Der BrugMarcelUSACHARACTERIZATION OF TAU FRAGMENTATION IN ALZHEIMER’S DISEASE CORTEX AND CSF
Van der ZeeJulieBelgiumTBK1 MUTATION SPECTRUM AND FREQUENCY IN AN EUROPEAN STUDY COHORT OF FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS PATIENTS
Van KolenKristofBelgiumDEVELOPMENT AND CHARACTERIZATION OF AN IN VIVO TAU SEEDING MODEL TO EVALUATE THE EFFICACY OF ANTI-TAU ANTIBODIES
Van WestenDanielleSwedenPERIVASCULAR SPACES IN THE HIPPOCAMPUS ARE ASSOCIATED WITH MARKERS OF VASCULAR DISEASE, AND NOT OF ALZHEIMER'S DISEASE
VanceJefferyUSAGENOME-WIDE METHYLATION ANALYSIS OF THE DORSAL MOTOR NUCLEUS OF THE VAGUS DEMONSTRATES EPIGENETIC CHANGES AS A CONTRIBUTION TO THE RISK OF PD
VassarRobertUSABACE1: PROMISE AND CHALLENGES AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE
VigliettaVissiaUSA12-MONTH INTERIM ANALYSIS OF APOE4 CARRIERS FOR FIXED AND TITRATION DOSING REGIMENS IN PRIME, A PHASE 1B STUDY OF ADUCANUMAB
Vijaya KumarDeepak KumarUSAABETA PEPTIDE AGGLUTINATES AND NEUTRALIZES ENDOTOXINS RELEASED DURING INFECTION
VillemagneVictorAustraliaCOMBINATION OF CONTINUOUS AND CATEGORICAL TAU BURDEN MEASURES OBTAINED WITH THREE DIFFERENT TAU TRACERS: 18F-AV1451, 18F-THK5317 AND 18F-THK5351
VirdeeJasmeetUnited KingdomEVALUATING FUNCTIONAL READOUTS IN ORGANOTYPIC HIPPOCAMPAL SLICES IN AN EX-VIVO MODEL OF TAU AGGREGATION
VögleinJonathanGermanySEIZURES IN FAMILIAL ALZHEIMER’S DISEASE
VoigtAaronGermanyCAG REPEAT TRANSLATIONAL FIDELITY AS A THERAPEUTIC AVENUE FOR TREATING POLYGLUTAMINE DISEASE
WagnerMatiasGermanyCLINICAL WHOLE EXOME SEQUENCING IN 66 PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA
WagnerLisaUSAAGE-DEPENDENT, SELECTIVE DOPAMINERGIC NEURODEGENERATION, PROTEIN ACCUMULATION AND AUTOPHAGY IMPAIRMENT IN LRRK-DEFICIENT MICE
WalkerLaurenUnited KingdomINVESTIGATING THE EFFECTS OF MULTIPLE PATHOLOGICAL LESIONS ON MOTOR DYSFUNCTION
WalterJochenGermanyPATHOLOGICAL VARIANTS OF AMYLOID Β-PLAQUES AND CEREBRAL AMYLOID ANGIOPATHY IN ALZHEIMER'S DISEASE
WangLi-SanUSAROLE AND RESOURCES OF NATIONAL INSTITUTE ON AGING GENETICS OF ALZHEIMER’S DISEASE DATA STORAGE SITE AND GENOME CENTER FOR ALZHEIMER’S DISEASE
WaningerShaniUSASUSTAINED ATTENTION AND MEMORY TASKS WITH CONCURRENT EEG PROVIDE POTENTIAL BIOMARKERS FOR MILD COGNITIVE IMPAIRMENT
WattersonDaniel Martin USANEW CANDIDATES FOR CNS STRESS KINASE MODULATION IN CNS DISORDERS
WattmoCarinaSwedenTHE OUTCOMES OF DIFFERENT ASSESSMENT SCALES CAN PREDICT SURVIVAL IN PATIENTS WITH ALZHEIMER’S DISEASE
WautersSandrineUnited KingdomMETHODOLOGY OF CULTURING FIBROBLASTS FROM PATHOLOGICALLY CONFIRMED NEURODEGENERATIVE DISORDERS
WeggenSaschaGermanyPATHOGENIC ABETA PRODUCTION BY HETEROZYGOUS PRESENILIN-1 (PSEN1) MUTANTS REQUIRES CATALYTIC ACTIVITY AND IS NOT MEDIATED BY CONFORMATIONAL HINDRANCE OF WILD TYPE PSEN1
WegmannSusanneUSAMISFOLDING AND AGE INFLUENCE HUMAN TAU PROPAGATION AND PATHOLOGY IN MICE
WeihofenAndreasUSABINDING AND FUNCTIONAL CHARACTERIZATION OF HUMAN-DERIVED ANTI-ALPHA-SYNUCLEIN ANTIBODY BIIB054
WeinerMichaelUSAVALIDATION OF AMYLOID AND TAU BIOMARKERS FOR AD DIAGNOSIS AND THERAPY-MONITORING: ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI)
WeinerHowardUSAIMMUNE MECHANISMS IN ALZHEIMER’S DISEASE
WestawayDavidCanadaINBRED MODELS OF 4-REPEAT TAUOPATHY WITH SLOW PATHOGENESIS REVEAL FOCAL AND DIVERSE PATTERNS OF TAU ACCUMULATION
WestmanEricSwedenSUBTYPES OF ALZHEIMER’S DISEASE BASED ON PATTERNS OF BRAIN ATROPHY: LONGITUDINAL TRAJECTORIES AND CLINICAL APPLICATIONS
WilcockDonnaUSATHE ROLE OF NEUROVASCULAR ASTROCYTES IN DEMENTIA
WilhelmusMichaThe NetherlandsBLOOD-DERIVED FACTOR XIIIA FORMS UNIQUE COMPLEXES WITH AΒ IN CEREBRAL AMYLOID ANGIOPATHY
WillemMichaelGermanyETA-SECRETASE PROCESSING OF APP INHIBITS HIPPOCAMPAL NEURONAL ACTIVITY
WillénKatarinaSwedenESCRT DEPENDENT ACCUMULATION OF ALZHEIMER’S AΒ IN ENDOSOMES AND THE EFFECT OF AΒ ON ENDOSOMAL ENLARGEMENT
WolozinBenjaminUSAREDUCTION OF THE RNA BINDING PROTEIN TIA1 PROTECTS AGAINST TAUOPATHY INDEPENDENT OF TAU AGGREGATION
WongPhilipUSAAN ALZHEIMER’S MODEL FOR DETERMINING FACTORS NECESSARY TO DRIVE THE CONVERSION OF TAU
WraySelinaUnited KingdomINVESTIGATING TAU PATHOLOGY IN ALZHEIMER’S DISEASE AND FRONTOTEMPORAL DEMENTIA USING PATIENT-DERIVED NEURONS
WszolekZbigniewUSACSF1R-RELATED LEUKOENCEPHALOPATHY
XuHuaxiUSAA NEW ROLE FOR THE AD-RISK COMPONENT SORLA IN NEUROPROTECTION FROM AMYLOID TOXICITY
YablonskiyDmitriyUSAIN VIVO DETECTION OF BRAIN PATHOLOGY IN PRECLINICAL AND EARLY ALZHEIMER DISEASE WITH GRADIENT ECHO PLURAL CONTRAST MRI
Young-PearseTracyUSACELL-TYPE DEPENDENT ALZHEIMER'S DISEASE PHENOTYPES: PROBING THE BIOLOGY OF SELECTIVE NEURONAL VULNERABILITY
YueZhenyuUSAUNCOVERING THE SIGNALING TRANSDUCTION PATHWAYS FOR PARKINSON’S GENE LRRK2 IN CENTRAL NERVOUS SYSTEM
YueChunmeiChinaHUMAN INDUCED NEURAL PROGENITORS FUNCTION PROPERLY IN ANIMAL MODELS OF ALZHEIMER’S DISEASE
ZetterbergHenrikSwedenFLUID BIOMARKERS FOR AD AND PD - RELATION TO PATHOLOGY, IMAGING AND CLINICAL DISEASE PROGRESSION
ZhangYuUSAPATTERNS OF BRAIN MICROSTRUCTURAL DEGENERATION DIFFERENTIATE CLINICALLY DIAGNOSED PROGRESSIVE SUPRANUCLEAR PALSY AND CORTICOBASAL DEGENERATION FROM PARKINSON’S DISEASE
ZhangJianhuaUSAREGULATION OF AUTOPHAGY, MITOCHONDRIAL DYNAMICS AND CELLULAR BIOENERGETICS BY 4-HYDROXYNONENAL IN PRIMARY NEURONS
ZhouJiaweiChinaHSP22/BRG3 MEDIATES THE DIFFERENTIAL DEGENERATION OF MIDBRAIN DOPAMINERGIC NEURONS
ZlokovicBerislavUSABLOOD BRAIN BARRIER DYSFUNCTION, NEURODEGENERATION AND ALZHEIMER’S DISEASE
ZunkeFriederikeUSAFORMATION OF TOXIC A-SYNUCLEIN ASSEMBLIES BY GLUCOSYLCERAMIDE IN HUMAN MIDBRAIN DOPAMINE NEURONS




AD/PD™ Facebook
AD/PD™ Twitter
AD/PD™ Network

Keep Me Updated